HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

C Belizna, F Pregnolato, S Abad, J Alijotas-Reig, H Amital, Z Amoura, L Andreoli, E Andres, A Aouba, S Apras Bilgen, L Arnaud, B Bienvenu, V Bitsadze, P Blanco, M Blank, MO Borghi, A Caligaro, E Candrea, V Canti, L ChicheJM Chretien, JW Cohen Tervaert, L Damian, T Delross, E Dernis, K Devreese, A Djokovic, E Esteve-Valverde, M Favaro, C Fassot, R Ferrer-Oliveras, A Godon, M Hamidou, M Hasan, D Henrion, B Imbert, PY Jeandel, P Jeannin, P Jego, N Jourde-Chiche, J Khizroeva, O Lambotte, C Landron, JO Latino, E Lazaro, K de Leeuw, T Le Gallou, L Kiliç, M Limper, L Loufrani, R Lubin, N Magy-Bertrand, G Mahe, A Makatsariya, T Martin, C Muchardt, G Nagy, L Omarjee, P Van Paasen, G Pernod, F Perrinet, G Pïres Rosa, MA Pistorius, A Ruffatti, F Said, P Saulnier, D Sene, L Sentilhes, O Shovman, J Sibilia, C Sinescu, N Stanisavljevic, L Stojanovich, LS Tam, A Tincani, F Tollis, S Udry, MN Ungeheuer, M Versini, R Cervera, PL Meroni

Research output: Contribution to journalArticlepeer-review


The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS. © 2018
Original languageEnglish
Pages (from-to)1153-1168
Number of pages16
JournalAutoimmunity Reviews
Issue number12
Publication statusPublished - 2018


Dive into the research topics of 'HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this